Humacyte, Inc. 8-K

What Happened

• Humacyte, Inc. announced on March 19, 2026 (filed via Form 8‑K) that it entered into securities purchase agreements to sell 25,000,000 shares of common stock in a registered direct offering priced at $0.80 per share. Gross proceeds are $20.0M; net proceeds are expected to be approximately $18.4M after placement agent fees and offering expenses. The offering is expected to close on or about March 20, 2026, subject to customary closing conditions. The company also entered a placement agent agreement with Titan Partners Group LLC.

Key Details

• Shares offered: 25,000,000 common shares
• Price per share: $0.80; gross proceeds: $20.0 million; expected net proceeds: ~$18.4 million
• Agreements dated: March 19, 2026; expected close: on or about March 20, 2026
• Offering made under the company’s effective Form S‑3 shelf registration (File No. 333‑290231, declared effective Sept 22, 2025); placement agent: Titan Partners Group LLC

Why It Matters

• This transaction provides Humacyte with fresh capital (about $18.4M net) to support its operations and corporate needs. Because new shares are being issued, the offering will dilute existing shareholders’ ownership percentage. The offering uses the company’s existing S‑3 registration, and the agreements include customary closing conditions and indemnities; a press release announcing the pricing was issued March 19, 2026.